Nonclinical teams spend real effort on S1B(R1)'s six-factor weight-of-evidence case for skipping the two-year rat bioassay. Fewer spend the same effort on the decision that comes before it: whether ICH S1A requires a carcinogenicity assessment at all. Get the S1A call wrong in either direction — testing a drug that never needed it, or skipping testing a drug that did — and the S1B(R1) conversation never gets a chance to matter.
The question S1A exists to answer
Adopted by the ICH Steering Committee in November 1995 and issued as FDA guidance the following year, S1A was written to stop a default assumption: that a long-term rodent carcinogenicity program is simply what pharmaceutical development requires once a compound reaches a certain stage. It is not. S1A frames carcinogenicity testing as a targeted response to a specific risk profile, built from two controlling factors — duration and pattern of clinical use, and the presence of cause-for-concern findings that apply independent of duration — rather than a fixed checkpoint every program clears on a schedule.
Duration of use is the first test, not the only one
S1A's starting premise is that risk from a potential carcinogen scales with how much of it a patient is exposed to over time. Drugs given once or briefly for an acute condition carry a materially different carcinogenic-risk profile than drugs a patient takes continuously, or repeatedly over years for a chronic disease. S1A's duration test sorts programs along that line: continuous or frequently repeated chronic use is the population the guideline expects to carry a full carcinogenicity assessment, while infrequent or short-duration use generally does not need one — provided nothing else about the compound says otherwise.
That qualifier is the part teams underweight. S1A does not let a short dosing course close the question on its own; it only removes duration as a reason to test. Severity and life-expectancy considerations for the treated population can also shift the calculus — a drug for a serious condition with short patient life expectancy may not need carcinogenicity data in hand before approval, for reasons that have nothing to do with how long the drug is dosed.
Duration of use tells you which population a drug is in. It does not, by itself, tell you the drug is clean. Why cause for concern is a separate test
Cause for concern overrides duration either way
The second test runs independent of the first, and it can push a program in either direction. S1A lists the kinds of findings that raise concern regardless of how briefly a drug is meant to be used:
- Genotoxicity signals. Positive findings from the genotoxicity weight-of-evidence case are the most direct cause-for-concern trigger — a compound with genotoxic potential does not get a duration-based pass.
- Structure-activity relationships. Structural similarity to a known carcinogen raises the question even absent a positive assay result of its own.
- Repeat-dose tissue findings. Preneoplastic or proliferative lesions observed in standard repeat-dose toxicology studies are a direct signal, not a footnote to be explained away.
- Tissue accumulation. Significant retention of the parent compound or its metabolites in tissue over time changes the exposure calculus duration alone does not capture.
- Hormonal or immune effects. Perturbation of hormonal status or sustained immune suppression are both independently associated with carcinogenic risk in the guideline's framework.
- Characterize duration and pattern of use first. Continuous, chronic-intermittent, or short-course — the category the rest of the analysis depends on.
- Screen every cause-for-concern factor on its own. Any single factor can trigger testing regardless of duration.
- Write the no-testing case down, not just the testing case. A reviewer who does not see a carcinogenicity study in the package will look for the documented rationale.
- Only then open the S1B(R1) question. The weight-of-evidence waiver evaluates how to test, for programs S1A has already placed in the testing population.
None of this replaces a structured nonclinical development program built around the actual compound in front of you rather than a generic template. Teams that treat S1A as a box checked once, early, and never revisited miss the cases where a late-emerging genotoxicity or repeat-dose finding reopens a question duration alone had seemed to settle. Teams that document the determination properly — and keep it current as nonclinical data accumulates — are the ones positioned to use S1B(R1)'s weight-of-evidence option when it is actually available to them, instead of discovering late that the underlying S1A case was never made.
Frequently asked questions
Does every new drug need a carcinogenicity study?
No. ICH S1A exists precisely to make that determination rather than assume it. Drugs administered infrequently or for a limited duration of clinical use generally do not need long-term carcinogenicity studies, unless a cause-for-concern factor applies regardless of duration. Drugs intended for continuous use, or used repeatedly in a chronic disease, are the population S1A expects to carry a carcinogenicity assessment.
What counts as 'cause for concern' under ICH S1A?
S1A's cause-for-concern factors include evidence of carcinogenic potential from genotoxicity findings, structure-activity relationships to known carcinogens, preneoplastic or proliferative lesions seen in repeat-dose toxicology studies, significant tissue accumulation of the compound or its metabolites, and hormonal or immune-suppressive effects of the kind associated with carcinogenic risk. Any one of these can trigger testing even for a drug whose duration of use would otherwise not call for it.
How does S1A relate to S1B(R1)'s weight-of-evidence waiver?
S1A answers whether a carcinogenicity assessment is needed; S1B(R1) answers how to satisfy the rat-bioassay component of that assessment once it is. The S1B(R1) addendum's weight-of-evidence waiver only becomes a live question for a program S1A has already placed in the testing population — it is not a way around the S1A determination itself.
Sources & further reading
- FDA. S1A The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals. fda.gov
- HHS/FDA. S1A — The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals (guidance document). hhs.gov
This article is provided for general informational purposes and reflects the regulatory landscape as of November 2026. It is not legal or regulatory advice. Confirm the current ICH S1A determination for your specific compound with FDA, your regional regulatory authority, or qualified counsel before acting.